Interestingly, both murine and human CD133+ “tumor repopulating cell” (TRC)-derived tumors showed halted growth when treated with IFN-β and a quick re-growth after IFN-β withdrawal, indicating that IFN-β induces a reversible dormancy in melanoma cells. This evidence concerns the gene PROM1 and neoplasm.